

Sushant Sahastrabuddhe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8019534/publications.pdf>

Version: 2024-02-01

30
papers

529
citations

623188

14
h-index

642321

23
g-index

30
all docs

30
docs citations

30
times ranked

574
citing authors

#	ARTICLE	IF	CITATIONS
1	The Euvichol story – Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships. <i>Vaccine</i> , 2018, 36, 6606-6614.	1.7	56
2	Overview of the Typhoid Conjugate Vaccine Pipeline: Current Status and Future Plans. <i>Clinical Infectious Diseases</i> , 2019, 68, S22-S26.	2.9	52
3	Increasing rates of <i>Salmonella Paratyphi A</i> and the current status of its vaccine development. <i>Expert Review of Vaccines</i> , 2013, 12, 1021-1031.	2.0	50
4	Status of paratyphoid fever vaccine research and development. <i>Vaccine</i> , 2016, 34, 2900-2902.	1.7	41
5	Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead. <i>Clinical Infectious Diseases</i> , 2020, 71, S141-S150.	2.9	41
6	Sexually Transmitted Infections and Risk Behaviors Among Transgender Persons (Hijras) of Pune, India. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 72-78.	0.9	39
7	Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children. <i>Vaccine</i> , 2018, 36, 3794-3801.	1.7	36
8	Spatial and Temporal Patterns of Typhoid and Paratyphoid Fever Outbreaks: A Worldwide Review, 1990–2018. <i>Clinical Infectious Diseases</i> , 2019, 69, S499-S509.	2.9	25
9	Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method. <i>Microbial Pathogenesis</i> , 2016, 97, 19-26.	1.3	24
10	Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of <i>Salmonella typhi</i> polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. <i>PLoS ONE</i> , 2019, 14, e0211784.	1.1	16
11	25 Years after Vi Typhoid Vaccine Efficacy Study, Typhoid Affects Significant Number of Population in Nepal. <i>PLoS ONE</i> , 2014, 9, e77974.	1.1	15
12	Typhoid Fever surveillance and vaccine use - South-East Asia and Western Pacific regions, 2009-2013. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 855-60.	9.0	15
13	Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report. <i>Vaccine</i> , 2020, 38, 4476-4483.	1.7	14
14	Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study. <i>EClinicalMedicine</i> , 2020, 27, 100540.	3.2	14
15	Typhoid vaccine introduction: An evidence-based pilot implementation project in Nepal and Pakistan. <i>Vaccine</i> , 2015, 33, C62-C67.	1.7	13
16	Barriers to typhoid fever vaccine access in endemic countries. <i>Research and Reports in Tropical Medicine</i> , 2017, Volume 8, 37-44.	2.8	13
17	Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 529-540.	4.6	12
18	Formative Research and Development of an Evidence-Based Communication Strategy: The Introduction of Vi Typhoid Fever Vaccine Among School-Aged Children in Karachi, Pakistan. <i>Journal of Health Communication</i> , 2013, 18, 306-324.	1.2	9

#	ARTICLE	IF	CITATIONS
19	A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2â€“11â€“years: a phase II preliminary report. BMC Pediatrics, 2020, 20, 480.	0.7	7
20	Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT). PLoS Neglected Tropical Diseases, 2020, 14, e0008171.	1.3	7
21	One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine. International Journal of Infectious Diseases, 2020, 93, 102-107.	1.5	7
22	Spectroscopic characterisation of a series of Salmonella Typhi Vi-diphtheria toxoid glycoconjugate antigens differing in polysaccharide-protein ratio. Journal of Pharmaceutical and Biomedical Analysis, 2020, 181, 113100.	1.4	7
23	Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal. Human Vaccines and Immunotherapeutics, 2021, 17, 2149-2157.	1.4	5
24	The Need for an Information Communication and Advocacy Strategy to Guide a Research Agenda to Address Burden of Invasive Nontyphoidal Salmonella Infections in Africa. Clinical Infectious Diseases, 2015, 61, S380-S385.	2.9	3
25	Mapping the high burden areas of cholera in Nepal for potential use of oral cholera vaccine: An analysis of data from publications and routine surveillance systems. Asian Pacific Journal of Tropical Medicine, 2020, 13, 107.	0.4	3
26	Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose. Npj Vaccines, 2022, 7, 12.	2.9	2
27	Epidemiology of Typhoid in Nepal: Review of Literature to Identify High Burden Area for Potential Use of Typhoid Vaccine. Pediatric Infectious Disease, 2021, 3, 51-56.	0.0	1
28	Enteric Vaccines for Resource-Limited Countries: Current Status and Future Prospects. Pediatric Annals, 2011, 40, 351-357.	0.3	1
29	A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age. The Lancet Regional Health - Western Pacific, 2022, 24, 100484.	1.3	1
30	Typhoid Fever Vaccines. , 0, , 1005-1005.		0